Adaptimmune Therapeutics PLC ADR | Mutual Funds
Mutual Funds that own Adaptimmune Therapeutics PLC ADR
American Funds Small Cap World Fund
7,186,700
7.62%
394,000
0.22%
06/30/2018
Baillie Gifford Overseas Growth Fund - Global Discovery Fund
1,007,177
1.07%
35,773
1.76%
04/30/2018
Fidelity Select Biotechnology Portfolio
864,192
0.92%
-556,250
0.11%
07/31/2018
iShares Nasdaq Biotechnology ETF
756,266
0.8%
-9,891
0.09%
09/06/2018
Old Westbury Small & Mid Cap Fund
538,018
0.56%
263,600
0.09%
04/30/2018
492,837
0.52%
-46,031
0.82%
03/31/2018
Tekla Life Sciences Investors
396,500
0.42%
0
0.94%
12/31/2017
Edinburgh Worldwide Investment Trust Plc
370,780
0.39%
0
0.69%
10/31/2017
MGI Funds Plc - Mercer Global Small Cap Equity Fund
302,324
0.32%
302,324
0.23%
06/30/2017
Fidelity Advisor Biotechnology Fund
288,752
0.31%
-186,396
0.12%
07/31/2018
| Address |
60 Jubilee Avenue
Abingdon Oxfordshire OX14 4RX
United Kingdom
|
|
Employees
|
- |
| Website |
http://adaptimmune.com |
| Updated |
07/08/2019 |
| Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. |
